Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26648126 | 0.92 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL1855116 | 0.89 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL7669911 | 0.89 | TDP1 (0.49) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL2722347 | 0.89 | ALOX5 (0.53) | ALDH1A1MAPK1L3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL16672704 | 0.87 | TDP1 (0.51) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL24983131 | 0.87 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL3963428 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL18673 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1LMNA | |
| SCHEMBL19996583 | 0.87 | CA1 (0.51) | ALDH1A1MAPK1L3MBTL1TDP1CDC25B | |
| SCHEMBL24180469 | 0.87 | CA1 (0.51) | ALDH1A1MAPK1L3MBTL1TDP1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| CN-104412441-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | MITSUBISHI CHEM CORP | 2015-03-11 | — | — | CN | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-1027349-B1 | TETRAHYDROFURAN PHOSPHATE- AND HYDROXY ESTERS, AS PRODRUGS FOR THE CORRESPONDING ANTIFUNGAL AGENT | SCHERING CORP (US) | 2005-01-05 | — | — | EP | disclosed |
| CN-1125066-C | Tetrahydrofuran hydroxy esters as prodrugs of corresponding antifungal agents | SCHERING CORP (US) | 2003-10-22 | — | — | CN | disclosed |
| CN-1271356-A | Tetrahydrofuran phosphate- and hydroxy esters, as prodrugs for corresponding antifungal agent | SCHERING CORP (US) | 2000-10-25 | — | — | CN | disclosed |
| EP-1027349-A1 | TETRAHYDROFURAN PHOSPHATE- AND HYDROXY ESTERS, AS PRODRUGS FOR THE CORRESPONDING ANTIFUNGAL AGENT | SCHERING CORPORATION (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6043245-A | FUNGICIDES FOR TREATING OR PREVENTING FUNGAL INFECTION, ESPECIALLY ASPERGILLUS, CANDIDA, CYRPTOCOCCUS AND OPPORTUNISTIC INFECTIONS | SCHERING CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| WO-1999015522-A1 | TETRAHYDROFURAN PHOSPHATE- AND HYDROXY ESTERS, AS PRODRUGS FOR THE CORRESPONDING ANTIFUNGAL AGENT | SCHERING CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | ALDH1A1 1423/4885MAPK1 4216/4885L3MBTL1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.